CRESCENT BIOPHARMA, INC.
For the period ended Jun 30, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 31, 2025
CBIO$13.92+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash | $152,645 | $34,766 |
| Prepaid expenses and other current assets | 1,582 | 38 |
| Total current assets | 154,227 | 34,804 |
| Property and equipment, net | 193 | — |
| Operating lease right-of-use assets | 1,607 | — |
| Restricted cash | 106 | — |
| Other assets | 1,300 | 813 |
| Total assets | $157,433 | $35,617 |
| Liabilities, Convertible Preferred Shares, and Shareholders’ Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable | $1,648 | $107 |
| Accrued expenses and other current liabilities(1) | 7,608 | 2,225 |
| Related party accounts payable and other current liabilities | 5,183 | 7,221 |
| Operating lease liability, current | 211 | — |
| Warrant liability, related party | 2,096 | 61 |
| Total current liabilities | 16,746 | 9,614 |
| Long term liabilities | ||
| Operating lease liability, noncurrent | 1,433 | — |
| Notes payable, noncurrent(2) | — | 37,482 |
| Total liabilities | 18,179 | 47,096 |
| Commitments and contingencies (Note 12) | ||
| Convertible preferred shares: | ||
| Series Seed convertible preferred shares, $0.0001 par value; no shares and 20,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares and 20,000,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; liquidation preference of $0 and $4,000 as of June 30, 2025 and December 31, 2024, respectively | — | 4,000 |
| Shareholders’ equity (deficit): | ||
| Series A non-voting convertible preferred shares, $0.001 par value; 5,000,000 shares and no shares authorized as of June 30, 2025 and December 31, 2024, respectively; 2,890 shares and no shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 4,000 | — |
| Ordinary shares, $0.001 par value; 175,000,000 and 40,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively, 13,892,562 and 1,018,604 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 14 | 1 |
| Additional paid-in capital | 190,045 | 2,387 |
| Accumulated deficit | (54,805) | (17,867) |
| Total shareholders' equity (deficit) | 139,254 | (15,479) |
| Total liabilities, convertible preferred shares, and shareholders’ equity (deficit) | $157,433 | $35,617 |
(1)Includes related party amount of $341 as of December 31, 2024.
(2)Includes related party amount of $14,993 as of December 31, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.